{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:20Z","timestamp":1793915300842,"version":"4.8.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In light of recently published clinical reports and trials, the TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to review new data and to update previously published clinical and dosimetric recommendations for the treatment of hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The TheraSphere Global DSC is comprised of health care providers across multiple disciplines involved in the treatment of HCC with yttrium-90 (Y-90) glass microsphere\u2013based transarterial radioembolization (TARE). Literature published between January 2019 and September 2021 was reviewed, discussed, and adjudicated by the Delphi method. Recommendations included in this updated document incorporate both the results of the literature review and the expert opinion and experience of members of the committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Committee discussion and consensus led to the expansion of recommendations to apply to five common clinical scenarios in patients with HCC to support more individualized efficacious treatment with Y-90 glass microspheres. Existing clinical scenarios were updated to reflect recent developments in dosimetry approaches and broader treatment paradigms evolving for patients presenting with HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Updated consensus recommendations are provided to guide clinical and dosimetric approaches for the use of Y-90 glass microsphere TARE in HCC, accounting for disease presentation, tumor biology, and treatment intent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-022-05956-w","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:02:31Z","timestamp":1663372951000},"page":"328-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-1825","authenticated-orcid":false,"given":"Riad","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth A.","family":"Padia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau","family":"Toskich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Fowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cheenu","family":"Kappadath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"5956_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. The Lancet Gastroenterology & hepatology. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/s2468-1253(20)30290-9.","journal-title":"The Lancet Gastroenterology & hepatology"},{"key":"5956_CR2","doi-asserted-by":"crossref","unstructured":"Lam M, Garin E, Maccauro M, Kappadath SC, Sze D, Turkmen C, et al. A Global Evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with yttrium-90: the TARGET Study. European Journal of Nuclear Medicine and Molecular Imaging. 2022;in press.","DOI":"10.1007\/s00259-022-05774-0"},{"key":"5956_CR3","doi-asserted-by":"publisher","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY Study. Hepatology (Baltimore, Md). 2021. doi:https:\/\/doi.org\/10.1002\/hep.31819.","DOI":"10.1002\/hep.31819"},{"key":"5956_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48:580\u20133. https:\/\/doi.org\/10.1007\/s00259-020-04976-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.31318","volume":"73","author":"A Gabr","year":"2021","unstructured":"Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology (Baltimore, MD). 2021;73:998\u20131010. https:\/\/doi.org\/10.1002\/hep.31318.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"5956_CR6","doi-asserted-by":"publisher","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e1brega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"5956_CR7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","volume":"46","author":"R Salem","year":"2019","unstructured":"Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46:1695\u2013704. https:\/\/doi.org\/10.1007\/s00259-019-04340-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR8","doi-asserted-by":"publisher","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009;50:477\u201384. https:\/\/doi.org\/10.2967\/jnumed.108.056036.","DOI":"10.2967\/jnumed.108.056036"},{"key":"5956_CR9","doi-asserted-by":"publisher","unstructured":"Report 85: fundamental quantities and units for ionizing radiation. J ICRU. 2011;11:1\u201331. https:\/\/doi.org\/10.1093\/jicru\/ndr011.","DOI":"10.1093\/jicru\/ndr011"},{"key":"5956_CR10","first-page":"1209","volume":"47","author":"SA Gulec","year":"2006","unstructured":"Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47:1209\u201311.","journal-title":"J Nucl Med"},{"key":"5956_CR11","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1118\/1.3608909","volume":"38","author":"WA Dezarn","year":"2011","unstructured":"Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824\u201345. https:\/\/doi.org\/10.1118\/1.3608909.","journal-title":"Med Phys"},{"key":"5956_CR12","doi-asserted-by":"publisher","unstructured":"Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. Journal of Vascular and Interventional Radiology: JVIR. 2006;17:1425\u201339. https:\/\/doi.org\/10.1097\/01.Rvi.0000235779.88652.53.","DOI":"10.1097\/01.Rvi.0000235779.88652.53"},{"key":"5956_CR13","doi-asserted-by":"publisher","unstructured":"Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. Journal of Vascular and Interventional Radiology: JVIR. 2006;17:1251\u201378. https:\/\/doi.org\/10.1097\/01.Rvi.0000233785.75257.9a.","DOI":"10.1097\/01.Rvi.0000233785.75257.9a"},{"key":"5956_CR14","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1016\/s1051-0443(07)61790-4","volume":"13","author":"R Salem","year":"2002","unstructured":"Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. Journal of Vascular and Interventional Radiology: JVIR. 2002;13:S223\u20139. https:\/\/doi.org\/10.1016\/s1051-0443(07)61790-4.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jvir.2017.02.018","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, et al. Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. Journal of Vascular and Interventional Radiology: JVIR. 2017;28:777-85.e1. https:\/\/doi.org\/10.1016\/j.jvir.2017.02.018.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR16","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jhep.2020.02.024","volume":"72","author":"A Gabr","year":"2020","unstructured":"Gabr A, Ranganathan S, Mouli SK, Riaz A, Gates VL, Kulik L, et al. Streamlining radioembolization in UNOS T1\/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol. 2020;72:1151\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.024.","journal-title":"J Hepatol"},{"key":"5956_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2147\/jhc.S319215","volume":"8","author":"C De la Garza-Ramos","year":"2021","unstructured":"De la Garza-Ramos C, Overfield CJ, Montazeri SA, Liou H, Paz-Fumagalli R, Frey GT, et al. Biochemical safety of ablative yttrium-90 radioembolization for hepatocellular carcinoma as a function of percent liver treated. J Hepatocell Carcinoma. 2021;8:861\u201370. https:\/\/doi.org\/10.2147\/jhc.S319215.","journal-title":"J Hepatocell Carcinoma"},{"key":"5956_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jvir.2009.01.021","volume":"20","author":"JD Louie","year":"2009","unstructured":"Louie JD, Kothary N, Kuo WT, Hwang GL, Hofmann LV, Goris ML, et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. Journal of Vascular and Interventional Radiology: JVIR. 2009;20:606\u201313. https:\/\/doi.org\/10.1016\/j.jvir.2009.01.021.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-02898-y","author":"SI Stein","year":"2021","unstructured":"Stein SI, Soliman MM, Sparapani J, Doustaly R, Cobb BW, Malhotra A, et al. Conventional hepatic volumetry may lead to inaccurate segmental yttrium-90 radiation dosimetry. Cardiovasc Intervent Radiol. 2021. https:\/\/doi.org\/10.1007\/s00270-021-02898-y.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5956_CR20","doi-asserted-by":"publisher","unstructured":"Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1016\/S2468-1253(22)00091-7","DOI":"10.1016\/S2468-1253(22)00091-7"},{"key":"5956_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1055\/s-0039-1696648","volume":"36","author":"A Gabr","year":"2019","unstructured":"Gabr A, Riaz A, Mouli S, Desai K, Thornburg B, Salem R, et al. Modified radiation lobectomy: an evolving paradigm to convert patients to liver resection candidacy. Semin Interv Radiol. 2019;36:343\u20138. https:\/\/doi.org\/10.1055\/s-0039-1696648.","journal-title":"Semin Interv Radiol"},{"key":"5956_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo-20-507","volume":"12","author":"A Ahmed","year":"2021","unstructured":"Ahmed A, Stauffer JA, LeGout JD, Burns J, Croome K, Paz-Fumagalli R, et al. The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure. Journal of Gastrointestinal Oncology. 2021;12:751\u201361. https:\/\/doi.org\/10.21037\/jgo-20-507.","journal-title":"Journal of Gastrointestinal Oncology"},{"key":"5956_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.semnuclmed.2019.01.009","volume":"49","author":"A Gabr","year":"2019","unstructured":"Gabr A, Polineni P, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma. Semin Nucl Med. 2019;49:197\u2013203. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.01.009.","journal-title":"Semin Nucl Med"},{"key":"5956_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.surg.2020.12.012","volume":"169","author":"Y Bekki","year":"2021","unstructured":"Bekki Y, Marti J, Toshima T, Lewis S, Kamath A, Argiriadi P, et al. A comparative study of portal vein embolization versus radiation lobectomy with yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery. 2021;169:1044\u201351. https:\/\/doi.org\/10.1016\/j.surg.2020.12.012.","journal-title":"Surgery"},{"key":"5956_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00259-017-3845-7","volume":"45","author":"X Palard","year":"2018","unstructured":"Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45:392\u2013401. https:\/\/doi.org\/10.1007\/s00259-017-3845-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40658-021-00394-3","volume":"8","author":"C Chiesa","year":"2021","unstructured":"Chiesa C, Sjogreen-Gleisner K, Walrand S, Strigari L, Flux G, Gear J, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for (99m)Tc-MAA pre- and (90)Y peri-therapy dosimetry in liver radioembolization with (90)Y microspheres. EJNMMI Physics. 2021;8:77. https:\/\/doi.org\/10.1186\/s40658-021-00394-3.","journal-title":"EJNMMI Physics"},{"key":"5956_CR27","doi-asserted-by":"publisher","unstructured":"Allimant C, Deshayes E, Kafrouni M, Santoro L, de Verbizier D, Fourcade M, et al. Hepatobiliary scintigraphy and glass (90)Y radioembolization with personalized dosimetry: dynamic changes in treated and nontreated liver. Diagnostics (Basel, Switzerland). 2021;11. https:\/\/doi.org\/10.3390\/diagnostics11060931.","DOI":"10.3390\/diagnostics11060931"},{"key":"5956_CR28","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2967\/jnumed.118.224394","volume":"60","author":"S van der Velden","year":"2019","unstructured":"van der Velden S, Braat M, Labeur TA, Scholten MV, van Delden OM, Bennink RJ, et al. A pilot study on hepatobiliary scintigraphy to monitor regional liver function in (90)Y radioembolization. J Nucl Med. 2019;60:1430\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.224394.","journal-title":"J Nucl Med"},{"key":"5956_CR29","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1007\/s00261-020-02855-2","volume":"46","author":"M Syed","year":"2021","unstructured":"Syed M, Shah J, Montazeri SA, Grajo JR, Geller B, Toskich B. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma. Abdominal Radiology (New York). 2021;46:2182\u20137. https:\/\/doi.org\/10.1007\/s00261-020-02855-2.","journal-title":"Abdominal Radiology (New York)"},{"key":"5956_CR30","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.29691","volume":"68","author":"R Salem","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology (Baltimore, MD). 2018;68:1429\u201340. https:\/\/doi.org\/10.1002\/hep.29691.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"5956_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2009.09.006.","journal-title":"Gastroenterology"},{"key":"5956_CR32","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology (Baltimore, MD). 2013;57:1826\u201337. https:\/\/doi.org\/10.1002\/hep.26014.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"5956_CR33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s00330-016-4445-9","volume":"27","author":"B Gorodetski","year":"2017","unstructured":"Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27:526\u201335. https:\/\/doi.org\/10.1007\/s00330-016-4445-9.","journal-title":"Eur Radiol"},{"key":"5956_CR34","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","volume":"59","author":"N Abouchaleh","year":"2018","unstructured":"Abouchaleh N, Gabr A, Ali R, Al Asadi A, Mora RA, Kallini JR, et al. (90)Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med. 2018;59:1042\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.199752.","journal-title":"J Nucl Med"},{"key":"5956_CR35","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s00259-018-4064-6","volume":"45","author":"CL Ho","year":"2018","unstructured":"Ho CL, Chen S, Cheung SK, Leung YL, Cheng KC, Wong KN, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET\/CT and posttreatment (90)Y PET\/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45:2110\u201321. https:\/\/doi.org\/10.1007\/s00259-018-4064-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jhep.2012.09.003","volume":"58","author":"K Memon","year":"2013","unstructured":"Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2012.09.003.","journal-title":"J Hepatol"},{"key":"5956_CR37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261954","author":"JC Ahn","year":"2021","unstructured":"Ahn JC, Lauzon M, Luu M, Friedman ML, Kosari K, Nissen N, et al. Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: analysis of the US National Cancer Database. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.121.261954.","journal-title":"J Nucl Med"},{"key":"5956_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00270-019-02404-5","volume":"43","author":"L Cardarelli-Leite","year":"2020","unstructured":"Cardarelli-Leite L, Chung J, Klass D, Marquez V, Chou F, Ho S, et al. Ablative transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus. Cardiovasc Intervent Radiol. 2020;43:411\u201322. https:\/\/doi.org\/10.1007\/s00270-019-02404-5.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5956_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/liv.13220","volume":"37","author":"E Garin","year":"2017","unstructured":"Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver International: official journal of the International Association for the Study of the Liver. 2017;37:101\u201310. https:\/\/doi.org\/10.1111\/liv.13220.","journal-title":"Liver International: official journal of the International Association for the Study of the Liver"},{"key":"5956_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2967\/jnumed.114.145177","volume":"56","author":"E Garin","year":"2015","unstructured":"Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56:339\u201346. https:\/\/doi.org\/10.2967\/jnumed.114.145177.","journal-title":"J Nucl Med"},{"key":"5956_CR41","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1007\/s00259-020-04845-4","volume":"47","author":"C Chiesa","year":"2020","unstructured":"Chiesa C, Mira M, Bhoori S, Bormolini G, Maccauro M, Spreafico C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47:3018\u201332. https:\/\/doi.org\/10.1007\/s00259-020-04845-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jvir.2020.12.019","volume":"32","author":"B Toskich","year":"2021","unstructured":"Toskich B, Vidal LL, Olson MT, Lewis JT, LeGout JD, Sella DM, et al. Pathologic response of hepatocellular carcinoma treated with yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: a validation study. Journal of Vascular and Interventional Radiology: JVIR. 2021;32:518-26.e1. https:\/\/doi.org\/10.1016\/j.jvir.2020.12.019.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR43","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1002\/mp.14452","volume":"47","author":"MA Thomas","year":"2020","unstructured":"Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC. Planning dosimetry for (90) Y radioembolization with glass microspheres: evaluating the fidelity of (99m) Tc-MAA and partition model predictions. Med Phys. 2020;47:5333\u201342. https:\/\/doi.org\/10.1002\/mp.14452.","journal-title":"Med Phys"},{"key":"5956_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2021.12.013","author":"T Baker","year":"2021","unstructured":"Baker T, Tabrizian P, Zendejas I, Gamblin TC, Kazimi M, Boudjema K, et al. Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. HPB (Oxford). 2021. https:\/\/doi.org\/10.1016\/j.hpb.2021.12.013.","journal-title":"HPB (Oxford)"},{"key":"5956_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/jhc.S248314","volume":"7","author":"A Teyateeti","year":"2020","unstructured":"Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, et al. Survival outcomes for yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2020;7:117\u201331. https:\/\/doi.org\/10.2147\/jhc.S248314.","journal-title":"J Hepatocell Carcinoma"},{"key":"5956_CR46","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/jhc.S318865","volume":"8","author":"AO Kaseb","year":"2021","unstructured":"Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, et al. A prospective phase II study of safety and efficacy of sorafenib followed by (90)Y glass microspheres for patients with advanced or metastatic hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1129\u201345. https:\/\/doi.org\/10.2147\/jhc.S318865.","journal-title":"J Hepatocell Carcinoma"},{"key":"5956_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ijrobp.2018.05.062","volume":"102","author":"SC Kappadath","year":"2018","unstructured":"Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT\/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102:451\u201361. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.062.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5956_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","volume":"31","author":"C Zhan","year":"2020","unstructured":"Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. Journal of Vascular and Interventional Radiology: JVIR. 2020;31:25\u201334. https:\/\/doi.org\/10.1016\/j.jvir.2019.05.023.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1055\/s-0040-1719187","volume":"37","author":"H Javan","year":"2020","unstructured":"Javan H, Dayyani F, Abi-Jaoudeh N. Therapy in advanced hepatocellular carcinoma. Semin Interv Radiol. 2020;37:466\u201374. https:\/\/doi.org\/10.1055\/s-0040-1719187.","journal-title":"Semin Interv Radiol"},{"key":"5956_CR50","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00259-019-04465-7","volume":"47","author":"A Jadoul","year":"2020","unstructured":"Jadoul A, Bernard C, Lovinfosse P, G\u00e9rard L, Lilet H, Cornet O, et al. Comparative dosimetry between (99m)Tc-MAA SPECT\/CT and (90)Y PET\/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47:828\u201337. https:\/\/doi.org\/10.1007\/s00259-019-04465-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13550-019-0533-6","volume":"9","author":"M Kafrouni","year":"2019","unstructured":"Kafrouni M, Allimant C, Fourcade M, Vauclin S, Guiu B, Mariano-Goulart D, et al. Analysis of differences between (99m)Tc-MAA SPECT- and (90)Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy. EJNMMI Res. 2019;9:62. https:\/\/doi.org\/10.1186\/s13550-019-0533-6.","journal-title":"EJNMMI Res"},{"key":"5956_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40658-020-00302-1","volume":"7","author":"N Meyers","year":"2020","unstructured":"Meyers N, Jadoul A, Bernard C, Delwaide J, Lamproye A, Detry O, et al. Inter-observer variability of (90)Y PET\/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization. EJNMMI Physics. 2020;7:29. https:\/\/doi.org\/10.1186\/s40658-020-00302-1.","journal-title":"EJNMMI Physics"},{"key":"5956_CR53","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/mnm.0000000000001395","volume":"42","author":"P d'Abadie","year":"2021","unstructured":"d\u2019Abadie P, Walrand S, Hesse M, Annet L, Borbath I, Van den Eynde M, et al. Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry. Nucl Med Commun. 2021;42:747\u201354. https:\/\/doi.org\/10.1097\/mnm.0000000000001395.","journal-title":"Nucl Med Commun"},{"key":"5956_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","volume":"79","author":"A Riaz","year":"2011","unstructured":"Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.062.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5956_CR55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (Baltimore, MD). 2014;60:192\u2013201. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"5956_CR56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1148\/radiol.2016160718","volume":"283","author":"DM Biederman","year":"2017","unstructured":"Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology. 2017;283:895\u2013905. https:\/\/doi.org\/10.1148\/radiol.2016160718.","journal-title":"Radiology"},{"key":"5956_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jvir.2017.08.026","volume":"29","author":"DM Biederman","year":"2018","unstructured":"Biederman DM, Titano JJ, Korff RA, Fischman AM, Patel RS, Nowakowski FS, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. Journal of Vascular and Interventional Radiology: JVIR. 2018;29:30-7.e2. https:\/\/doi.org\/10.1016\/j.jvir.2017.08.026.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR58","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1148\/radiol.2018171768","volume":"287","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050\u20138. https:\/\/doi.org\/10.1148\/radiol.2018171768.","journal-title":"Radiology"},{"key":"5956_CR59","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00259-017-3792-3","volume":"44","author":"R Ali","year":"2017","unstructured":"Ali R, Riaz A, Gabr A, Abouchaleh N, Mora R, Al Asadi A, et al. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging. 2017;44:2195\u2013202. https:\/\/doi.org\/10.1007\/s00259-017-3792-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR60","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1007\/s00259-015-3122-6","volume":"42","author":"VL Gates","year":"2015","unstructured":"Gates VL, Hickey R, Marshall K, Williams M, Salzig K, Lewandowski RJ, et al. Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction? Eur J Nucl Med Mol Imaging. 2015;42:2038\u201344. https:\/\/doi.org\/10.1007\/s00259-015-3122-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR61","doi-asserted-by":"publisher","unstructured":"Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics: a review publication of the Radiological Society of North America, Inc. 2008;28:81\u201399. https:\/\/doi.org\/10.1148\/rg.281065721.","DOI":"10.1148\/rg.281065721"},{"key":"5956_CR62","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1055\/s-0035-1564704","volume":"32","author":"C Molvar","year":"2015","unstructured":"Molvar C, Lewandowski R. Yttrium-90 radioembolization of hepatocellular carcinoma-performance, technical advances, and future concepts. Semin Interv Radiol. 2015;32:388\u201397. https:\/\/doi.org\/10.1055\/s-0035-1564704.","journal-title":"Semin Interv Radiol"},{"key":"5956_CR63","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.jvir.2013.07.011","volume":"24","author":"N Hamoui","year":"2013","unstructured":"Hamoui N, Minocha J, Memon K, Sato K, Ryu R, Salem R, et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. Journal of Vascular and Interventional Radiology: JVIR. 2013;24:1743\u20135. https:\/\/doi.org\/10.1016\/j.jvir.2013.07.011.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR64","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00259-016-3438-x","volume":"43","author":"A Gabr","year":"2016","unstructured":"Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, et al. Same-day (90)Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging. 2016;43:2353\u20139. https:\/\/doi.org\/10.1007\/s00259-016-3438-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00270-007-9064-z","volume":"30","author":"RJ Lewandowski","year":"2007","unstructured":"Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571\u201392. https:\/\/doi.org\/10.1007\/s00270-007-9064-z.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"526\u201335","key":"5956_CR66","doi-asserted-by":"publisher","first-page":"35.e1","DOI":"10.1053\/j.gastro.2011.04.054","volume":"141","author":"K Memon","year":"2011","unstructured":"Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141(526\u201335):35.e1-2. https:\/\/doi.org\/10.1053\/j.gastro.2011.04.054.","journal-title":"Gastroenterology"},{"key":"5956_CR67","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep.29480","volume":"67","author":"A Riaz","year":"2018","unstructured":"Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, et al. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. Hepatology (Baltimore, MD). 2018;67:873\u201383. https:\/\/doi.org\/10.1002\/hep.29480.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"5956_CR68","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00259-013-2674-6","volume":"41","author":"C Spreafico","year":"2014","unstructured":"Spreafico C, Maccauro M, Mazzaferro V, Chiesa C. The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging. 2014;41:634\u20138. https:\/\/doi.org\/10.1007\/s00259-013-2674-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR69","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","volume":"59","author":"M Vouche","year":"2013","unstructured":"Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59:1029\u201336. https:\/\/doi.org\/10.1016\/j.jhep.2013.06.015.","journal-title":"J Hepatol"},{"key":"5956_CR70","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1245\/s10434-013-2906-9","volume":"20","author":"J Edeline","year":"2013","unstructured":"Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, et al. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518\u201325. https:\/\/doi.org\/10.1245\/s10434-013-2906-9.","journal-title":"Ann Surg Oncol"},{"key":"5956_CR71","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.4254\/wjh.v9.i36.1372","volume":"9","author":"M Vouche","year":"2017","unstructured":"Vouche M, Degrez T, Bouazza F, Delatte P, Galdon MG, Hendlisz A, et al. Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. World J Hepatol. 2017;9:1372\u20137. https:\/\/doi.org\/10.4254\/wjh.v9.i36.1372.","journal-title":"World J Hepatol"},{"key":"5956_CR72","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00270-021-02810-8","volume":"44","author":"MM Matsumoto","year":"2021","unstructured":"Matsumoto MM, Mouli S, Saxena P, Gabr A, Riaz A, Kulik L, et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-patient analysis. Cardiovasc Intervent Radiol. 2021;44:1070\u201380. https:\/\/doi.org\/10.1007\/s00270-021-02810-8.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5956_CR73","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijrobp.2018.01.116","volume":"101","author":"KT Chan","year":"2018","unstructured":"Chan KT, Alessio AM, Johnson GE, Vaidya S, Kwan SW, Monsky W, et al. Prospective trial using internal pair-production positron emission tomography to establish the yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;101:358\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.116.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5956_CR74","unstructured":"Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So. 2011;55:168\u201397."},{"key":"5956_CR75","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jvir.2016.12.1221","volume":"28","author":"P Haste","year":"2017","unstructured":"Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography\/CT. Journal of Vascular and Interventional Radiology: JVIR. 2017;28:722-30.e1. https:\/\/doi.org\/10.1016\/j.jvir.2016.12.1221.","journal-title":"Journal of Vascular and Interventional Radiology: JVIR"},{"key":"5956_CR76","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/mp.12695","volume":"45","author":"A Balagopal","year":"2018","unstructured":"Balagopal A, Kappadath SC. Characterization of (90) Y-SPECT\/CT self-calibration approaches on the quantification of voxel-level absorbed doses following (90) Y-microsphere selective internal radiation therapy. Med Phys. 2018;45:875\u201383. https:\/\/doi.org\/10.1002\/mp.12695.","journal-title":"Med Phys"},{"key":"5956_CR77","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1007\/s00259-015-3068-8","volume":"42","author":"C Chiesa","year":"2015","unstructured":"Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42:1718\u201338. https:\/\/doi.org\/10.1007\/s00259-015-3068-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5956_CR78","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00270-011-0295-7","volume":"35","author":"R Seidensticker","year":"2012","unstructured":"Seidensticker R, Seidensticker M, Damm R, Mohnike K, Sch\u00fctte K, Malfertheiner P, et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol. 2012;35:1109\u201318. https:\/\/doi.org\/10.1007\/s00270-011-0295-7.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5956_CR79","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00259-015-3157-8","volume":"43","author":"E Garin","year":"2016","unstructured":"Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT\/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43:559\u201375. https:\/\/doi.org\/10.1007\/s00259-015-3157-8.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05956-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T18:03:59Z","timestamp":1673201039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05956-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5956"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05956-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Riad Salem is a consultant for Boston Scientific, AstraZeneca, Genentech, Sirtex, Cook, Eisai, Bard, and QED Therapeutics.Siddharth Padia is a consultant for Boston Scientific Corporation, Teleflex Medical, Guerbet, Varian Medical Systems, and Johnson and Johnson.Marnix Lam is a consultant for Boston Scientific, Terumo, and Quirem, and he receives research support from Boston Scientific, Terumo, Quirem, and Novartis.Carlo Chiesa is a consultant for Terumo and Boston Scientific, and he received a research grant in 2017 from the latter company.Paul Haste is a consultant for Boston Scientific.Bruno Sangro received consulting fees from Adaptimmune, Astra-Zeneca, Bayer, BMS, Boston Scientific, Eisai, Exelixis, Eli-Lilly, IPSEN, Merck, Onxeo, Roche, Sirtex, and Terumo; lecture fees from Astra-Zeneca, Bayer, BMS, Eisai, Eli-Lilly, Incyte, IPSEN, Roche, and Sirtex; and institutional research grants from BMS and Sirtex.Beau Toskich is a consultant for AstraZeneca, Genentech, Eisai, Boston Scientific, Sitrex Medical, Turnstone Biologics, Johnson and Johnson, HistoSonics, and VIVOS.Kirk Fowers is an employee of Boston Scientific Corporation.Joseph M. Herman is a consultant for Boston Scientific and HistoSonics and received institutional support for the Canopy Cancer Collective Learning Health Network.S. Cheenu Kappadath has been a consultant for Boston Scientific, Sirtex Medical, ABK Biomedical, and Terumo Medical.Thomas Leung is a consultant for Boston Scientific, SIRTEX, AstraZeneca, Eisai, and Ipsen.Daniel Y. Sze was a consultant for Argon, Artio Medical, Astra-Zeneca, Bayer, BlackSwan Vascular, Boston Scientific, Bristol-Myers Squibb, Eisai, FluidX, W. L. Gore, Guerbet, Koli, RadiAction, Sirtex, Terumo, TriSalus Life Sciences, and Varian; received institutional research support from Boston Scientific, Merit Medical, and Sirtex; and serves on Independent Data Safety Monitoring Boards for W. L. Gore and Replimune.Edward Kim is an advisory board member, speaker, and consultant for Boston Scientific; a consultant for Bristol-Myers Squibb; and an advisory board member for Genentech and Eisai.Etienne Garin is a consultant for Boston Scientific.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}